This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Antares Pharma, Inc.
11/4/2021
Welcome to the Ontaris Pharma Third Quarter 2021 Financial and Operating Results Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. If you would like to ask a question, please press star 1. Again, that is star 1 if you would like to ask a question. I will now hand the conference call over to Tram Bui, Antares Vice President of Corporate Communications and Investor Relations.
Thank you, Operator, and good morning, everyone. Earlier today, we announced our third quarter 2021 financial results and operating achievements. A copy of the press release and slide presentation for today's conference call are available in the Investor Relations section of the Antares Pharma corporate website. Before we begin, I'd like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include those related to our future financial and operating results, including our expectations regarding the impact of the ongoing COVID-19 pandemic on our overall business, operating results and financial condition, our ability to achieve the updated 2021 revenue guidance, future revenue growth, prescription volumes, product launches and market share for our products and our partner products, FDA actions and potential regulatory approval for our and our partner products, timing and results of ongoing and future development programs, and clinical trials for our products and our partner products and future business development efforts. These board-looking statements are subject to certain risks and uncertainties, and actual results could differ materially. They are identified and described in today's press release in the accompanying slide presentation on slide two and in the company's filings with the SEC on form 10-K and as updated in Antares' recent periodic filings on form 10-Q and form 8-K. Antares is providing this information as of the date of today's conference call and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events, or circumstances after the date hereof, except as required by law or otherwise. The company cautions investors not to place undue reliance on these forward-looking statements. Joining me on the call today are Bob Apples, President and Chief Executive Officer, Fred Powell, Executive Vice President and Chief Financial Officer, Dr. Peter Richardson, Executive Vice President, Research and Development and Chief Medical Officer, and Joe Renda, Senior Vice President of Commercial. Let's review the agenda for today's call on slide three. Bob will begin with a review of our overall business, including the recent licensing agreement for Tolando, and then hand the call over to Joe to provide an update on our commercial achievements and strategy for our proprietary portfolio. Dr. Peter Richardson will then discuss our R&D initiatives, before handing the call back to Bob to provide a review of our Alliance business. Fred will then go through the detailed financials, and Bob will conclude with closing comments before opening the line for your questions. Please turn to slide four, and I will hand the call over to Bob Apple. Bob?
Thanks, Charm, and good morning, everyone. And thank you for your interest in our third quarter results and operations update. As we look at the third quarter and year-to-date results, we are very pleased to report another record period of growth. We believe the operational and financial advancements we have achieved across our business is reflective of the strength of our organization and highlights the multiple and sustainable opportunities that remain in front of us. Our third quarter and nine-month revenue increased 20% and 28% year-over-year to more than $48 and $135 million. EBITDA in the third quarter increased to $11 million and approximately $29 million in a nine-month period. And then income before taxes increased 45% in Q3, to $7.2 million, and over 250% to $17.2 million in a nine-month period. We achieved these impressive results through an extremely challenging time with the emergence of the Delta variant, affecting patient visits and physician access, as well as putting tremendous pressure on supply chain from our manufacturers and suppliers. Even with the strong headwinds in play, Zyestad and Tevis Generic EpiPen continue to be the primary contributors to our growth again this quarter. We also expect the recent licensing of Talando and the development of ATRS 1902 for Adrenal Crisis Rescue will further enhance our proprietary portfolio and be future drivers of our overall growth. Furthermore, we anticipate these internal achievements, coupled with the potential opportunities that remain with our alliance business, will create a foundation to continue to grow our business. Let me first start with the signing of the U.S. license for Talando in October, which is a twice-daily oral treatment for testosterone replacement therapy, tentatively approved by the FDA. We have committed to broadening our commercial proprietary portfolio, and the opportunity to complement our existing therapeutic footprint with another testosterone offering to physicians and patients significantly enhances our near-term growth opportunities. Within the backdrop of a large and growing TRT market, we have a sales force that continues to prove their success with Zyvested that we expect can seamlessly leverage their physician relationships to drive adoption of an oral dosage form of testosterone. Based on our discussions with physicians and patients, it is our understanding that there is a preference for more than one therapy option, and our growing commitment to TRT will support our market share gains and revenue growth in this market. Overall, we've remained fiscally diligent with prospecting for corporate development and believe the financial terms of the license agreement with an upfront payment of $11 million represents an attractive opportunity with a compelling story and natural fit. We expect to launch this complimentary product in the second quarter of 2022 upon FDA approval based on the expiration of an exclusivity period of a competing product. From a market standpoint, We believe Talando has several positive product attributes, such as one dose of strength and less restrictive dosing instructions, among others, that could set it apart from the other oral products. We also expect to conduct further diligence and assess the development opportunity for Talando XR, a potential once-daily oral treatment for testosterone replacement therapy, which we believe could represent a significant benefit for patients and physicians. Let me now turn the call over to Joe to provide an overview of our commercial achievements and provide more detail on our commercial strategy for an expanded proprietary portfolio.
You're reading a preview of the ATRS Q3 2021 earnings call.
Free account.